Clinical Trial Update: A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial comparing SH006 Injection in combination therapy to Regorafenib for advanced hepatocellular carcinoma, with the study status NO…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• SH006 Injection (SH006)
• Stivarga (regorafenib)

Snippet

Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd. | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING